A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination with an anti-PD-1 Monoclonal Antibody in Adults with Advanced Solid Tumors

MC #21-29

NCT #
NCT05007782
Condition(s)
Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Vaginal Cancer, Vulvar Cancer
Molecular Target(s)
CCR8
Drug Classification(s)
Monoclonal Antibody
Agents(s)
monoclonal antibody
Phase(s)
I

Mechanism of Action

GS-GS-1811 is a monoclonal antibody that is designed to bind to CCR8. It is thought to target Tumor-Infiltrating T Regulatory cells for depletion by enhancing an antibody-dependent cellular cytotoxicity mechanism

Purpose

  • How much of the study agent when given alone or in combination with Zimberelimab can be given with an acceptable level of side effects
  • About the safety, tolerability, and effectiveness of the study agent when given alone or in combination with Zimberelimab
  • Whether the study agent in combination with Zimberelimab or Zimberelimab alone is more effective
  • How much of the study agent is absorbed into your blood and how fast it is removed from your blood
  • If research tests can be used in the future to predict who will benefit from GS1811
  • How your body responds to taking GS-1811 alone or in combination with Zimberelimab

Location

MCD

Similar Trials

Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Trispecific Antibodies
Yes
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
MCD
JIT-MCLA-128-CL01
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
n/a
NRG1 fusion
Lung Cancer (NSCLC), Pancreatic Cancer
MCD
JIT-MCLA-129-CL01
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
n/a
EGFR, MET
Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC)
MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.